These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 35857854)

  • 1. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Schwersenz I; Walter MC; Baumann M; Baumgartner M; Deschauer M; Eisenkölbl A; Flotats-Bastardas M; Hahn A; Horber V; Husain RA; Illsinger S; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stögmann E; Trollmann R; Vill K; Weiß C; Wiegand G; Ziegler A; Lochmüller H; Kirschner J;
    Brain; 2023 Feb; 146(2):668-677. PubMed ID: 35857854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug treatment for spinal muscular atrophy type I.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.
    Hepkaya E; Kılınç Sakallı AA; Ülkersoy İ; Başkan AK; Arslan H; Meral Ö; Dilek TD; Güler S; Saltık S; Çokuğraş H
    Pediatr Int; 2022 Jan; 64(1):e15310. PubMed ID: 36310036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
    Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
    J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy.
    Kokaliaris C; Evans R; Hawkins N; Mahajan A; Scott DA; Sutherland CS; Nam J; Sajeev G
    Adv Ther; 2024 Jun; 41(6):2414-2434. PubMed ID: 38705943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Bertsche A; Vill K; Baumann M; Baumgartner M; Cordts I; Eisenkölbl A; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Horber V; Husain RA; Illsinger S; Jahnel J; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schwerin-Nagel A; Reihle C; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Trollmann R; Weiler M; Weiß C; Wiegand G; Wilichowski E; Ziegler A; Lochmüller H; Kirschner J;
    Orphanet J Rare Dis; 2022 Oct; 17(1):384. PubMed ID: 36274155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
    Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
    BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
    Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
    Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function.
    Pane M; Coratti G; Sansone VA; Messina S; Catteruccia M; Bruno C; Sframeli M; Albamonte E; Pedemonte M; Brolatti N; Mizzoni I; D'Amico A; Bravetti C; Berti B; Palermo C; Leone D; Salmin F; De Sanctis R; Pera MC; Piastra M; Genovese O; Ricci F; Cavallina I; Masson R; Zanin R; Agosto C; Salomon E; Bruno I; Magnolato A; Bertini E; Tiziano FD; Bovis F; Mercuri E;
    Eur J Neurol; 2023 Jun; 30(6):1755-1763. PubMed ID: 36880698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience.
    Łusakowska A; Wójcik A; Frączek A; Aragon-Gawińska K; Potulska-Chromik A; Baranowski P; Nowak R; Rosiak G; Milczarek K; Konecki D; Gierlak-Wójcicka Z; Burlewicz M; Kostera-Pruszczyk A
    Orphanet J Rare Dis; 2023 Aug; 18(1):230. PubMed ID: 37542300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.
    Hagenacker T; Wurster CD; Günther R; Schreiber-Katz O; Osmanovic A; Petri S; Weiler M; Ziegler A; Kuttler J; Koch JC; Schneider I; Wunderlich G; Schloss N; Lehmann HC; Cordts I; Deschauer M; Lingor P; Kamm C; Stolte B; Pietruck L; Totzeck A; Kizina K; Mönninghoff C; von Velsen O; Ose C; Reichmann H; Forsting M; Pechmann A; Kirschner J; Ludolph AC; Hermann A; Kleinschnitz C
    Lancet Neurol; 2020 Apr; 19(4):317-325. PubMed ID: 32199097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvements in Walking Distance during Nusinersen Treatment - A Prospective 3-year SMArtCARE Registry Study.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Steinbach M; Blaschek A; Baumann M; Baumgartner M; Becker B; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Küpper H; Johannsen J; Kamm C; Koch JC; Köhler C; Kölbel H; Kolzter K; von Moers A; Naegel S; Neuwirth C; Petri S; Rödiger A; Schimmel M; Schrank B; Schreiber G; Smitka M; Stadler C; Steiner E; Stögmann E; Trollmann R; Türk M; Weiler M; Stoltenburg C; Willichowsky E; Zeller D; Ziegler A; Lochmüller H; Kirschner J;
    J Neuromuscul Dis; 2023; 10(1):29-40. PubMed ID: 36565133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland.
    Tscherter A; Rüsch CT; Baumann D; Enzmann C; Hasselmann O; Jacquier D; Jung HH; Kruijshaar ME; Kuehni CE; Neuwirth C; Stettner GM; Klein A;
    Neuromuscul Disord; 2022 May; 32(5):399-409. PubMed ID: 35337708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Post-Marketing Surveillance Study of Nusinersen for Spinal Muscular Atrophy in Routine Medical Practice in China: Interim Results.
    Jiang Y; Wang Y; Xiong H; Li W; Luo R; Chen W; Yin F; Lü J; Liang J; Chen WJ; Lu X; Wang H; Tang J; Monine M; Makepeace C; Jin X; Foster R; Chin R; Berger Z
    Adv Ther; 2024 Jul; 41(7):2743-2756. PubMed ID: 38722537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen.
    Weststrate H; Stimpson G; Thomas L; Scoto M; Johnson E; Stewart A; Muntoni F; Baranello G; Conway E;
    Dev Med Child Neurol; 2022 Jul; 64(7):907-914. PubMed ID: 35103306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nusinersen induces detectable changes in compound motor action potential response in spinal muscular atrophy type 1 patients with severe impairment of motor function.
    Ueda Y; Egawa K; Kawamura K; Ochi N; Goto T; Kimura S; Narugami M; Nakakubo S; Nakajima M; Manabe A; Shiraishi H
    Brain Dev; 2024 Mar; 46(3):149-153. PubMed ID: 38103972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
    Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
    Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
    Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
    Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.